Tag - phase 3

Pfizer and Valneva announced topline Phase 3 VALOR data for their investigational 6‑valent OspA-based Lyme disease vaccine candidate PF‑07307405 (LB6V), reporting more than 70% efficacy in preventing Lyme disease in...